Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 159

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 159
---
  |
| Effect of exchange rates                        |    992 |         |        |
| Net sales at constant exchange rates (non-IFRS) | 42,073 |  37,817 | +11.3% |

(a) Figures for the comparative period (2023) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. To facilitate analysis and comparisons with prior periods, some figures are given at CER. We calculate net sales at CER by recalculating net sales for the relevant period using the exchange rates that were used for the previous period. 1/ Net sales by operating segment Our net sales comprise the net sales generated by our Biopharma segment.

| (€ million)       |   2024 | 2023(a) | Change on areported basis(IFRS) | Change at constantexchange rates(non-IFRS) |
| Biopharma segment | 41,081 |  37,817 | +8.6%                           | +11.3%                                     |
| Total net sales   | 41,081 |  37,817 | +8.6%                           | +11.3%                                     |

(a) Figures for the comparative period (2023) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.

| SANOFIFORM 20-F2024 | 73 |

| PART I                                               |
| ITEM 5. Operating and Financial Review and Prospects |

2/ Net sales by medicine, vaccine and geography – 2024 compared with 2023

| (€ million)                                | Total sales | Change(reported) | Change(CER) | UnitedStates | Change(CER) | Europe | Change(CER) | Rest ofthe world | Change(CER) |
| Immunology                                 |             |                  |             |              |             |        |             |                  |             |
| Dupixent                                   |      13,072 | +22.0%           | +23.1%      |        9,544 | +17.2%      |  1,618 | +31.9%      |            1,910 | +50.8%      |
| Kevzara                                    |         424 | +18.8%           | +21.0%      |          246 | +26.2%      |    121 | +5.2%       |